• The specific situation of the patient. Unless otherwise provided for by national regulations,
off-label use of medication should be limited to situations where it is in the patient's interest …

Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Aim: The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure” replaces
the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the “2017 …

Most patients survive acute myocardial infarction (MI). Yet this encouraging development
has certain drawbacks: heart failure (HF) prevalence is increasing and patients affected tend …

2023 ESC Guidelines for the management of acute coronary syndromes Page 1 2023 ESC
Guidelines for the management of acute coronary syndromes Developed by the task force on …

Computational drug repurposing aims to identify new indications for existing drugs by
utilizing high-throughput data, often in the form of biomedical knowledge graphs. However …

Background In patients with symptomatic heart failure, sacubitril–valsartan has been found
to reduce the risk of hospitalization and death from cardiovascular causes more effectively …

Arterial hypertension is a leading cause of death globally. Due to ageing, the rising
incidence of obesity, and socioeconomic and environmental changes, its incidence …

In this update of the Canadian Cardiovascular Society heart failure (HF) guidelines, we
provide comprehensive recommendations and practical tips for the pharmacologic …

The Japanese Society of Hypertension (JSH) revised the Guidelines for the Management of
Hypertension 2014 (JSH 2014), and published the JSH 2019. In the development of the JSH …